"As a world-class expert in the physical chemistry of DNA, as an inventor, entrepreneur, and researcher, Mike has much to contribute immediately, and will play a key role in moving the company to the next levels in the future.
STONY BROOK, NY (PRWEB) July 30, 2014
July 30, 2014. Applied DNA Sciences, Inc.(OTCQB: APDN), (Twitter: @APDN), a biotechnology firm that provides DNA-based authentication and security solutions and services, has appointed Dr. Michael E. Hogan, Ph.D. Vice President of Life Sciences, a newly created position, with a starting date in mid-September.
Dr. Hogan will lead APDN’s drive to build its business in pharmaceuticals anti-counterfeiting, to form business relationships with biotech and healthcare customers, provide guidance to APDN’s R&D efforts, and apply his considerable experience to development of APDN’s in-field DNA analysis technology, among other responsibilities.
Dr. James A. Hayward, President and CEO of Applied DNA Sciences, said, "As a world-class expert in the physical chemistry of DNA, as an inventor, entrepreneur and researcher, Mike Hogan has much to contribute immediately, and we believe he will play a key role in moving the company to the next levels in the future. Our science and management base has gained another great talent and we are fortunate to have attracted him to our team."
Dr. Hogan has 25 years of experience in translational science; breakthroughs in the use of DNA as therapeutics, as the basis for in vitro diagnostics, and the broad area of biospecimen stabilization have been particular areas of focus. He was an early pioneer in the development of lab-on-a-chip in his work as professor at Baylor College of Medicine, in collaboration with MIT Lincoln Laboratory and Genometrix, a company that he co-founded to commercialize those technologies.
Dr. Hogan was awarded his Ph.D. with highest distinction by Yale University. He earned his B.S. in Biology from Dartmouth College, where he graduated Summa cum Laude.
As a researcher and entrepreneur in pharmaceuticals, Dr. Hogan has had extensive interaction with the U.S. Food and Drug Administration and other relevant government agencies. He was Chief Science Officer and Co-founder of Triplex Pharmaceuticals, one of the early biopharma players in the area of DNA therapy.
He holds 25 U.S. patents and many more international patents. He has considerable experience in managing large grant awards, directing as Principal Investigator large NIH, DoD, DARPA and NIST funded programs including RO1, PO1 and SBIR Grants based on national-scale collaboration among engineers, chemists and the clinical sciences.
Dr. Hogan commented, "Applied DNA Sciences has developed a high-value suite of technologies to take the lead in the new field of nucleic acid-based authentication and supply chain protection. This technology platform entails the application of DNA biophysics and applied genetics of the kind that have been my interest over the past two decades in pharmaceutics, advanced diagnostic test development and biospecimen preservation. I look forward to using my expertise to help guide the Applied DNA technology platform into its next generation, with special focus on developing a leadership role for the company in its application to pharmaceutical supply chain protection and the coupling of core technologies to nanotechnology and to the next generation of nucleic acid sequencing."
About Applied DNA Sciences
APDN is a provider of botanical-DNA based security and authentication solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature® DNA describes the uncopyable marker that is at the heart of all of our security and authentication solutions. SigNature DNA is at the core of a family of products such as DNAnet®, our anti-theft product, SigNature® T, targeted toward textiles, and digitalDNA®, providing powerful track and trace. All provide a forensic chain of evidence and can be used to prosecute perpetrators.
The statements made by APDN may be forward-looking in nature. Forward-looking statements describe APDN’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of APDN. Actual results could differ materially from those projected due to our short operating history, limited financial resources, limited market acceptance, market competition and various other factors detailed from time to time in APDN’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 20, 2013 (amended on May 1, 2014) and our subsequent quarterly reports on Form 10-Q/A (for the quarterly period ended December 31, 2013) and Form 10-Q. APDN undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events.